For months, the working assumption in the response to the Democratic Republic of the Congo's Ebola outbreak has been simple and grim: the world's two licensed Ebola vaccines target the wrong strain, and there is nothing on the shelf.
New laboratory data complicate that. Researchers tested blood from 179 West African adults and children who had received one of the two licensed Zaire Ebola vaccines and found measurable antibody activity against Bundibugyo virus, the strain driving the current outbreak. The findings were published in the New England Journal of Medicine and reported by CIDRAP.
